# Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes

> **NCT04588259** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 331 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Faster aspart
- **DRUG:** Insulin aspart
- **DRUG:** Insulin degludec

## Key facts

- **NCT ID:** NCT04588259
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-09
- **Primary completion:** 2022-07-05
- **Final completion:** 2022-08-05
- **Target enrollment:** 331 (ACTUAL)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04588259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04588259, "Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04588259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*